AstraZeneca is planning to expand its role as a drug supplier in China to becoming a wider provider of healthcare through its use of robotics and other tech.
The combination of the Novartis drugs dabrafenib and trametinib for patients with stage 3 skin cancer will be funded by the NHS in England and Wales after a recommendation from cost regulat
